Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC29A1 | Q99808 | 4/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.49 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.49 |
| ▸ | ADK | P55263 | 1/20 | 0.48 |
| ▸ | TRDMT1 | O14717 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27426560 | 0.89 | SLC29A1 (0.62) | SLC29A1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL27425390 | 0.89 | SLC29A1 (0.62) | SLC29A1ADORA3ADORA1ADORA2AADORA2B | |
| SCHEMBL27424490 | 0.89 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1PRKAG1PRKAA1 | |
| SCHEMBL27428243 | 0.89 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27424987 | 0.89 | SLC29A1 (0.57) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27428648 | 0.86 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1 | |
| SCHEMBL27426759 | 0.86 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1ADORA2A | |
| SCHEMBL27426665 | 0.86 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1TRDMT1 | |
| SCHEMBL27425126 | 0.86 | SLC29A1 (0.59) | SLC29A1ADORA3ADORA1ADORA2APRKAG1 | |
| SCHEMBL27434392 | 0.86 | SLC29A1 (0.59) | SLC29A1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024134541-A1 | HETEROCYCLIC COMPOUNDS AS ENT INHIBITORS AND COMPOUNDS FOR USE IN THE TREATMENT OF CANCERS | iTeos Belgium SA (BE) | 2024-06-27 | — | — | WO | disclosed |